Insulin analogs

What are insulin analogs?

Insulin analogs are modified forms of human insulin, the peptide hormone (two chains totaling 51 amino acids) that lowers blood sugar. By changing a few amino acids or adding a fatty-acid chain, chemists adjusted how quickly insulin is absorbed and how long it lasts, without changing what it does at the receptor. The main analogs fall into two groups:

Detemir was discontinued in the U.S. at the end of 2024. The first analog, lispro, was approved in the United States in 1996.

The history of insulin analogs

Insulin itself was one of the great medical breakthroughs of the twentieth century, first used to treat diabetes in the early 1920s and transforming a fatal disease into a manageable one. For decades, patients used animal-derived and later recombinant human insulin, but these did not match the body's natural pattern well: regular insulin acted too slowly for meals, and intermediate insulin produced peaks and troughs overnight. The analogs, beginning with lispro in 1996 and glargine in 2000, were engineered specifically to fix those mismatches, giving faster mealtime insulins and flatter, longer basal insulins.

How do insulin analogs work?

Insulin analogs bind the insulin receptor on muscle, fat, and liver cells, just as natural insulin does. Activating the receptor prompts cells to take up glucose from the blood (through the GLUT4 transporter), stimulates storage of glucose, fat, and protein, and suppresses the liver's production of glucose, all of which lower blood sugar. The amino-acid changes in the analogs do not alter this core action; they change the pharmacokinetics, how fast the insulin is absorbed and how long it lingers.

Rapid-acting analogs are engineered so their molecules separate and absorb quickly after injection, matching the glucose rise from a meal, while basal analogs are designed to precipitate or to bind albumin so they release slowly and provide flat, all-day coverage. Combining the two reproduces the body's natural pattern more closely than older insulins. In the Treat-to-Target trial, adding a basal analog to oral drugs let a larger share of patients reach their HbA1c goal without documented nighttime low blood sugar, compared with older NPH insulin.

Are they FDA-approved?

Yes. Insulin analogs have been FDA-approved since 1996, starting with lispro, followed by glargine in 2000 and others including aspart, glulisine, detemir, and degludec. They are approved to improve blood-sugar control in adults and, for many products, children with diabetes.

What are insulin analogs prescribed for?

Insulin analogs are prescribed for type 1 diabetes, where insulin is essential, and for type 2 diabetes when other treatments are not enough. Treatment is individualized, often combining a basal analog for background coverage with a rapid-acting analog at meals, delivered by pen, syringe, or pump.

What are the side effects?

According to product labels such as the Humalog prescribing information, the most common and important side effect is:

• Low blood sugar (hypoglycemia), which can be severe

Other effects include:

• Weight gain
• Injection-site reactions or fatty lumps (lipodystrophy)
• Low potassium

More serious considerations include:

• Severe hypoglycemia, which can cause seizures or loss of consciousness
• Fluid retention and heart failure when combined with certain diabetes pills (thiazolidinediones)

Insulin pens must never be shared between people, even if the needle is changed.

Sources: FDA prescribing information for insulin analog products (Humalog, NovoLog, Lantus, Levemir, Tresiba, and others); the Treat-to-Target trial (Riddle et al., Diabetes Care, 2003, DOI: 10.2337/diacare.26.11.3080), indexed on PubMed; and historical accounts of the discovery of insulin. This document is educational and does not constitute medical advice.